Ann: June 2017 Appendix 4C - Quarterly, page-2

Some very thin supply on the order books back to the values pre-SAE.

A confirmation that the unfortunate SAE 2 months ago was not derived from the trial medication from PTX will easily bring us back to the ball park of 8c and above.

Quarterlies confirming that with about $8 million on hand, and a projected $1 million expenditure next quarter, there shouldn't be any looming need for cash. It'll be on Said and his researching team to continue delivering on medical breakthrough, and Steven with his finance, commercial credentials to elevate the shareholders value.

But first order of business, ensure the overhang of SAE is clarified...